Smith & Nephew (LON:SN) Price Target Raised to GBX 1,400 at Deutsche Bank Aktiengesellschaft

Key Points

• Deutsche Bank raised the target price for Smith & Nephew from GBX 1,300 ($17.37) to GBX 1,400 ($18.70), indicating a potential upside of 4.67%.
• JPMorgan Chase also increased their price target for the stock, from GBX 1,357 ($18.13) to GBX 1,438 ($19.21), with an "overweight" rating.
• Smith & Nephew has a market cap of £14.66 billion and operates through segments including Orthopaedics and Advanced Wound Management.

Smith & Nephew (LON:SN - Get Free Report) had its target price raised by research analysts at Deutsche Bank Aktiengesellschaft from GBX 1,300 ($17.48) to GBX 1,400 ($18.83) in a research report issued on Wednesday, Marketbeat Ratings reports. The brokerage currently has a "hold" rating on the stock. Deutsche Bank Aktiengesellschaft's price objective would indicate a potential upside of 4.13% from the stock's previous close.

Separately, JPMorgan Chase & Co. lifted their price objective on Smith & Nephew from GBX 1,357 ($18.25) to GBX 1,438 ($19.34) and gave the stock an "overweight" rating in a report on Wednesday.

Smith & Nephew Price Performance

SN stock traded up GBX 7 ($0.09) during mid-day trading on Wednesday, hitting GBX 1,344.50 ($18.08). 2,958,968 shares of the stock were exchanged, compared to its average volume of 343,671. The company has a debt-to-equity ratio of 70.22, a current ratio of 2.51 and a quick ratio of 0.84. The firm's 50 day simple moving average is GBX 1,129.06 and its two-hundred day simple moving average is GBX 1,079.76. The company has a market cap of £14.74 billion, a PE ratio of 48.41, a price-to-earnings-growth ratio of 0.46 and a beta of 0.62.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.